Published April 2025
We just released our latest update on the pharmaceutical commercialization landscape. The pharmaceutical industry is racing to offset a looming patent cliff, with >$350B in annual sales at risk by 2030, and outsourced commercialization partners are playing a critical role in that strategy. If you are a founder, executive, or investor in the space, we hope you find this report helpful as you plan for the year ahead.
Key takeaways from Q1:
- Surge in platform creation and add-on M&A activity
- Secondary buyouts gaining steam as larger sponsors consolidate the consolidators
- Continued push toward full-service models with expanded regulatory, HEOR, and market access capabilities
- Growing role of AI, digital analytics, and patient-centric strategies
- Deepening focus on rare disease, cell & gene, and other high-growth therapeutic areas
Please see the following link to a copy of the blinded report. If you would like access to a full copy of the update, please email us at pharmacommercialization@providenthp.com.
